Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116571 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
A Phase 2 study, sponsored by QLT.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00116571 is a Phase 2 study that was terminated before completion, run by QLT. The registered enrollment target is 180 participants.
The verdict
NCT00116571, a Phase 2 study, was terminated before completion, sponsored by QLT.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "light-activated". Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue. This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.
Interventions
- DRUG Lemuteporfin for injection
- DEVICE Transurethral drug delivery system
- DEVICE Transurethral light delivery system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116571
The ClinicalTrials.gov registry entry for NCT00116571 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QLT, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lemuteporfin for injection is the first listed.
NCT00116571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116571 about?
NCT00116571 is a clinical study titled "Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)". The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "l...
What is the current status of trial NCT00116571?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2005-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00116571?
The interventions under investigation include: Lemuteporfin for injection (DRUG), Transurethral drug delivery system (DEVICE), Transurethral light delivery system (DEVICE).
Who is sponsoring clinical trial NCT00116571?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.